{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreifxacisodqpr3xspn3tlkf273gy7x266piqcg7e3w2xwmvmxdu4ju",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mfmpyhcp2xx2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihs4yniv5gslv4xxwpwazmdqvpsj3sble4olz6hvbzdguafle3ihy"
    },
    "mimeType": "image/jpeg",
    "size": 123080
  },
  "path": "/pharmalot/2026/02/24/fda-novo-obesity-wegovy-ozempic-novartis-jnj-bayer/?utm_campaign=rss",
  "publishedAt": "2026-02-24T14:23:12.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Pharma",
    "Pharmalot",
    "pharmalittle",
    "STAT+"
  ],
  "textContent": "The Trump administration released detailed guidance for approving the first bespoke medicines crafted to treat individual patient mutations",
  "title": "STAT+: Pharmalittle: We’re reading about an FDA plan for ultra-rare drugs, Novo cutting GLP-1 drug prices, and more",
  "updatedAt": "2026-02-24T14:23:16.000Z"
}